ArticleAIDS (London, England)2025
Microbial translocation and gut damage is associated with hepatic fibrosis but not steatosis in women with and without HIV.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Higher plasma kynurenine-tryptophan ratio predicts incident hepatic fibrosis in women with HIV.AIDS (London, England) · 2026Article
- PREVALENCE AND SEVERITY OF STEATOTIC LIVER DISEASE IN WOMEN WITH AND WITHOUT HIV.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives.Frontiers in endocrinology · 2026Review
- Metabolic dysfunction-associated steatotic liver disease in people living with HIV: mechanisms, diagnosis, and management.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveMetabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in people living with HIV (PWH). Gut microbial translocation and gut damage may play a role in MASLD pathogenesis. We determined associations of circulating biomarkers of translocation and gut damage with hepatic steatosis and fibrosis in a large U.S. cohort of women with HIV (WWH) and without HIV.
designVibration controlled transient elastography (VCTE) was conducted from 2013 to 2018 among 854 WWH and 349 women without HIV. Serum biomarkers were measured within 6 months of the VCTE: kynurenine to tryptophan (KT) ratio, intestinal fatty acid binding protein (I-FABP), and immune activation markers soluble CD14 (sCD14) and soluble CD163 (sCD163).
methodsWe used multivariable linear regression to evaluate independent associations of each biomarker, HIV serostatus, and demographic, metabolic, and HIV-specific covariates with hepatic steatosis [controlled attenuation parameter (CAP)] and fibrosis [liver stiffness (LS)].
resultsIn multivariable analysis, increasing in KT ratio was associated with a 6 dB/m lower CAP and 6% higher LS, and sCD14 with a 5 dB/m lower CAP and 8% higher LS. sCD163 was not associated with CAP but was associated with a 12.5% higher LS value. I-FABP was not associated with either CAP or LS values.
conclusionsHigher KT ratio, sCD14, and sCD163 were associated with increased hepatic fibrosis but not steatosis. In fact, higher KT ratio and sCD14 were associated with decreased steatosis. This suggests that microbial translocation and gut damage may contribute to the pathogenesis of fibrosis in WWH in a mechanism unrelated to increased steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.